Back to results
US 10,479,997 B2Granted
Compositions and methods for diagnosis and treatment of prostate cancer
AssigneeNovartis AG
InventorsZineb Mounir, Raymond Pal Pagliarini
Life of this patent
Estimating the term…
Abstract
The invention provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating subjects having TMPRSS2:ERG positive prostate cancer, which we show is amenable to therapeutic treatment with a PRMT5 inhibitor. Kits, methods of screening for candidate PRMT5 inhibitors, and associated methods of treatment are also provided.
Claims10
A method of determining if a subject afflicted with prostate cancer will respond to therapeutic treatment with a PRMT5 inhibitor comprising
- (a) evaluating a test sample obtained from the subject for TMPRSS2:ERG positivity by at least detecting of the methylation of R761 of the Androgen Receptor, wherein TMPRSS2:ERG positivity indicates that the subject will respond to therapeutic treatment with a PRMT5 inhibitor;
- (b) determining the level and/or activity of PRMT5 in the subject, wherein (a) and (b) can be performed in any order;
- and (c) administering a therapeutically effective amount of a PRMT5 inhibitor to the subject, wherein the PRMT5 inhibitor is selected from the group consisting of a RNAi agent, a CRISPR, a TALEN, a zinc finger nuclease, an mRNA, an antibody or derivative thereof, an antibody-drug conjugate, a chimeric antigen receptor T cell (CART) or a low molecular weight compound.
Dependencies are inferred from the claim text.